AstraZeneca's Pipeline Reckoning: Ultomiris Fails in Adults, Shines in Kids

AstraZeneca delivered one of the most revealing single-day scorecards in pharma Monday — its blockbuster rare-disease drug Ultomiris failed a pivotal trial in adults, showed a lifeline in children, and the company bet on AI to prevent future stumbles, all while posting a quarterly profit beat that kept its $80 billion 2030 revenue dream alive.

Vital Signs

Key numbers from Monday's disclosures:

• 87.2% overall survival at 26 weeks for Ultomiris in pediatric...